Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
Sign Up to like & getrecommendations! Published in 2022 at "mBio"
DOI: 10.1128/mbio.01249-22
Abstract: SARS-CoV-2, the causative agent of COVID-19, continues to spread globally, with waves resulting from new variants that evade immunity generated by vaccines and previous strains and escape available monoclonal antibody therapy. Fusion-inhibitory peptides may provide… read more here.
Keywords: inhibitory lipopeptides; monoclonal antibody; sars cov; fusion inhibitory ... See more keywords